CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing R&D expenditure
4.1.2. Flourishing demand for outsourcing analytical testing and clinical trial services
4.1.3. Focus on drug discovery
4.1.4. Government Initiatives for research on rare diseases
4.2. Market Restraints & Challenges
4.2.1. Stringent regulations governing drug discovery & animal usage
4.2.2. The high cost of drug discovery and development
4.3. Market Opportunities
4.3.1. Patent expiries to boost the demand for drug discovery
4.3.2. Introduction of advanced technologies
CHAPTER 5. GLOBAL DRUG DISCOVERY SERVICES MARKET – BY PROCESS
5.1. Target selection
5.2. Target validation
5.3. Lead optimisation
5.4. Hit-to-lead identification
5.5. Candidate validation
CHAPTER 6. GLOBAL DRUG DISCOVERY SERVICES MARKET – BY DRUG
TYPE
6.1. Small Molecules
6.2. Biologics
CHAPTER 7. GLOBAL DRUG DISCOVERY SERVICES MARKET – BY TYPE
7.1. Medicinal chemistry
7.2. Biology services
7.3. Drug metabolism and pharmacokinetics
CHAPTER 8. GLOBAL DRUG DISCOVERY SERVICES MARKET – BY
THERAPEUTIC AREA
8.1. Oncology
8.2. Neurology
8.3. Cardiovascular diseases
8.4. Respiratory diseases
8.5. Diabetes
8.6. Others
CHAPTER 9. GLOBAL DRUG DISCOVERY SERVICES MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL DRUG DISCOVERY SERVICES MARKET - COMPANY
PROFILES
10.1. Thermo Fisher Scientific
10.2. Merck & Co., Ltd
10.3. GE Healthcare
10.4. Albany Molecular Research, Inc. (AMRI)
10.5. Charles River Laboratories
10.6. Evotec A.G.
10.7. Pharmaceutical Product Development, LLC. (Ppd)
10.8. Jubilant Biosys Ltd
10.9. Covance Inc.
10.10. Genscript Biotech Corporation
10.11. Aurigene Discovery Technologies
10.12. Wuxi AppTec Group
10.13. Syngene International Ltd
10.14. Pharmacometrics & Integrated Clinical Development
10.15. Contract Pharma
CHAPTER 11. GLOBAL DRUG DISCOVERY SERVICES MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
